Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Public Storage (PSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Public Storage — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Public Storage trades at $320.06 (market cap $56.28B). The key difference: Public Storage is the larger of the two by market cap, and Public Storage pays a 3.74% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PSA | |
|---|---|---|
Market Cap | $39.89B | $56.28B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $329.64 |
52-Week Low | $278.09 | $258.44 |
Enterprise Value | $38.15B | $70.53B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Public Storage (PSA) trades at $320.56, up 0.38% with a bullish technical signal. The company demonstrates strong profitability with 39.16% net margins and consistent earnings beats. Recent developments include a $900 million note offering to fund the National Storage Affiliates acquisition and expansion into Canadian markets, signaling growth ambitions. Analyst consensus targets $332.25 with 65.72% hold ratings.
PSA offers stable income with recent dividend payments but faces execution risks from expansion initiatives. Valuation multiples appear elevated with P/E of 33.12, requiring sustained growth to justify premium pricing. The stock's near-term performance hinges on Q2 2026 earnings results due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
